Insulin hypersensitivity-a rare occurrence with currently available insulin preparations-may have varied manifestations, ranging from a local injection site allergy to severe generalized anaphylactic reactions. While various additives included in commercial insulin preparations and insulin peptides themselves remain the primary allergens responsible, faulty injection technique may at times potentiate the development of insulin allergy. Management of insulin allergy is complex, potentially dangerous at times, and can be challenging for the treating physician. We report a case of insulin allergy due to intradermal insulin injections which was cured by adopting a proper injection technique.
INTRODUCTION
Hypersensitivity to insulin preparations, ranging from a minor local injection site allergy to severe generalized and at times life-threatening anaphylactic reactions, currently affects \4% of diabetic patients treated with insulin [1] . The insulin peptide itself and the various additives present in the formulations are proposed to be the allergens responsible. A faulty injection technique and the resulting intradermal insulin administration can facilitate the development of such allergic reactions.
CASE REPORT
A 65-year-old gentleman (body mass index 32.2 kg/m 2 ) with a 10-year history of type 2 diabetes presented with a month-long history of burning sensation followed by appearance of a pruritic maculopapular rash in and around the injection site within half an hour after insulin administration. He had been using oral antihistaminics and topical steroids for symptomatic relief during the previous two weeks without much effect while the rash kept appearing after each shot of insulin administered. Frustrated with the repetitive allergic reactions, he became desperate to find an effective noninjectable antidiabetic medication. However, due to low stimulated C-peptide levels (0.4 ng/ml), his primary care physician insisted on continuation of the existing insulin therapy, which led him to omit the scheduled doses of insulin in a desperate attempt to avoid unpleasant local adverse reactions. Three months prior to this presentation he had been prescribed a twice-daily premixed human insulin (30% regular and 70% neutral protamine Hagedorn) in view of sustained poor glycemic control with optimal dosage of oral antidiabetic drugs. During the initial 2 months, his daughter used to inject insulin into his anterior abdomen after being taught how to perform insulin injection by the care giver. During that period, the injections were virtually painless, and the patient noticed satisfactory glycemic control without any skin changes around the injection site. However, with the marriage of his daughter he had started to self-inject himself and noticed development of an itchy rash after each and every injection. He did not experience itching on other body parts, or any cough, wheeze, or shortness of breath. The insulin injection technique was rectified and the patient was advised to have a skin biopsy, which he declined. However, all of the rashes disappeared completely after 2 weeks and the patient did not notice similar symptoms after adopting the proper injection technique (Fig. 2) .
Causality analysis for intradermal insulin injection and the allergic cutaneous lesions was performed using the World Health Organization-Uppsala Monitoring Centre (WHO-UMC) causality assessment scale and the Naranjo adverse drug reaction probability scale, and it was found that intradermal injection was the probable cause of the adverse drug reaction [probable/likely on the WHO-UMC causality assessment scale and probable (total score 8) on the Naranjo probability scale]. 
DISCUSSION

CONCLUSION
Though faulty injection technique is a simple and easily treatable cause of injection site allergy in insulin-treated diabetics, it is often overlooked in clinical practice. To the best of our knowledge, such an association has rarely been described in the global literature [7] . To conclude, treating physicians should enquire about injection technique when managing patients with an insulin allergy, as this may avoid the need to explore other costly, complicated, and potentially dangerous treatment alternatives.
ACKNOWLEDGMENTS
No funding or sponsorship was received for this study or the publication of this article. All 
